相关实验视频
Updated: May 20, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.1K
陶罗二氧化酸改善了小鼠的DSS诱导的大肠炎.
Yunyun Zou1, Aziz Ghaderpour1, Bolormaa Munkhbileg2
1Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
International immunopharmacology
|July 16, 2023
概括
陶罗德氧基酸 (TDCA) 通过抑制炎症酶激活,有效地治疗小鼠的大肠炎. 这种新的治疗方法针对关键的炎症途径,为炎症性肠病 (IBD) 提供了潜在的新疗法.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 管理通常涉及药物治疗,对某些患者来说有效性有限或副作用显著.
- 现有的治疗方法包括5-氨基酸 (5-ASA),葡萄糖皮质类药物和针对TNFα,IL-12或IL-23的生物疗法.
- 炎症酶途径与IBD病原发生有关,这表明炎症酶抑制是治疗策略.
研究的目的:
- 为了研究taurodeoxycholate (TDCA) 的治疗潜力,一种G蛋白结合受体19 (GPCR19) 激动剂,在大肠炎的小鼠模型中.
- 阐明TDCA在IBD的背景下发挥抗炎作用的分子机制.
主要方法:
- 使用德克斯硫酸盐 (DSS) 诱导的小鼠结肠炎模型来评估TDCA的疗效.
- 在体外研究中使用骨髓衍生的巨细胞 (BMDMs) 来研究TDCA对炎症信号通路的影响.
- 研究的关键途径包括NF-κB激活,纯能受体P2X7 (P2X7R) 信号传递,NLRP3炎症酶激活和巨细胞两极分化.
主要成果:
- 服用TDCA显著改善了DSS诱导的大肠炎,防止体重减轻,结肠缩短和粘膜.
- TDCA抑制了促炎性细胞因子的产生,并减少了炎症细胞在结肠中的透.
- 在体外,TDCA抑制了NF-κB的激活,降低了P2X7R的表达,抑制了ATP诱导的调动,并阻止了NLRP3炎症酶组合和caspase-1/IL-1β成熟.
结论:
- 在大肠炎的小鼠模型中,TDCA显示出显著的治疗疗效.
- TDCA通过抑制NLRP3炎症酶通路的原始化和激活阶段来起作用.
- 这些发现表明,TDCA是针对炎症体信号的新型IBD治疗的有希望的候选者.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.